Bluejay Diagnostics, Inc. - Common Stock (BJDX)

Bitech Technologies Corp. (OTCQB: BTTC)an independent power provider developing utility-scale battery energy storage initiatives and innovative renewable solutions has appointed Montgomery Bannerman as an Independent Director, adding over 35 years of expertise in energy to its Board. Bannerman, a seasoned leader with roles as CEO ArcStar Energy, and CEO of Verso Technologies (NYSEVRS), brings valuable experience in renewable energy infrastructure. His background in developing large-scale renewable energy networks, including microgrid projects with MicroGrid Networks, aligns with Bitech’s strategy to expand Distributed Energy Resources Interconnections (DERI) and Distributed Photovoltaics (DPV) in key regions throughout the US.

Bluejay (NASDAQBJDX), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, recently announced the closing of a firm commitment underwritten public offering. Expected gross proceeds to the company were approximately $8.75 million. The base offering consisted of 5,368,098 common units or prefunded units, each unit consisting of one share of the company’s common stock or one pre-funded warrant to purchase one share of common Stock, two Class C warrants each to purchase one share of common stock and one Class D warrant to purchase such number of shares of common stock as determined in the Class D warrant. In addition, the company granted Aegis Capital Corp. a 45-day option to purchase additional shares of common stock and/or common warrants, representing up to 15% of the number of securities sold in the offering, solely to cover over-allotments, if any.

Bluejay (NASDAQBJDX) is a medical diagnostics company that offers the Symphony technology platform, Symphony Cartridge and tests and testing devices for the diagnosis of allergic conjunctivitis and monitoring of disease progression in critical care settings. Aegis Capital Corp. announced that it acted as exclusive placement agent on a ~$2.2 million private placement for Bluejay Diagnostics.

Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness 

ACTON, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQBJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced financial results for the quarter and six months ended June 30, 2022.

Bluejay Diagnostics (NASDAQBJDX), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, has announced that the FDA has agreed to consider Bluejay’s plan to pursue a De Novo submission for the Symphony IL-6 Test. “We are excited for the opportunity to pursue the De Novo regulatory pathway,” said Bluejay’s Chief Executive Officer Neil Dey. “This confirms our belief that the Bluejay Symphony IL-6 Test has the potential to provide an innovative solution to the market. Bluejay continues to advance the Symphony IL-6 Test towards the company’s anticipated marketing application with the FDA, expected by year-end 2022.”